The world's first whole exome sequence of small intestine neuroendocrine tumors has been completed by researchers at Mayo Clinic.
The latter is the most common cancer of the small bowel and one that responds poorly to chemotherapy. Sequence analysis revealed six pathways as potential drug targets for this type of cancer.
Carcinoid Tumors
Carcinoid tumors is a benign tumor that results in carcinoid syndrome. Only 8 to 10% of all carcinoid tumors are associated with the carcinoid syndrome.
Advertisement
MULTIMEDIA ALERT: Video of Dr. Banck is available for journalists to download on the Mayo Clinic News Network.
"This is a very important step in achieving targeted therapies and individualized treatment approaches for patients with small bowel carcinoids," says Michaela Banck, M.D., a Mayo oncologist and lead author of a new study in the June edition of the Journal of Clinical Investigation. "Genomic analysis of the individual patient's tumors will help us identify new drugs that are targeted to the individual's disease."
![Epigenetics]( "Epigenetics")
In the recent years 'epigenetics' represents inheritable changes in gene expression that do not include DNA alterations.
The study revealed genomic alterations that might be susceptible to chemotherapy in the majority of patients (72 percent). Accordingly, an implied therapeutic road map for small intestine carcinoids might feature many related, but distinct, paths defined by individualized approaches and pharmacogenomics.
Dr. Banck's team, including Mayo oncologist and senior author Andreas Beutler, M.D., sequenced the genes of small intestine neuroendocrine tumors from 48 patients, along with the normal (or germline) tissue of those same 48 patients. Comparative analysis of the 96 whole exome sequences revealed that small intestine neuroendocrine tumors carry low numbers of point mutations and characteristic recurrent patterns of gene duplications and losses.
The study was supported by grants from the Mayo Clinic Center for Individualized Medicine, Mayo Clinic, and The Richard M. Schulze Family Foundation.
Study authors also include Rahul Kanwar, Amit Kulkarni, M.B.B.S., Ganesh Boora, M.B.B.S., M.D., Franziska Metge*, Benjamin Kipp, Ph.D., Lizhi Zhang, M.D., Erik Thorland, Ph.D., Kay Minn*, Bruce Eckloff, Eric Wieben, Ph.D., Yanhong Wu, Ph.D., Julie M. Cunningham, Ph.D., David Nagorney, M.D., Judith Gilbert*, Matthew Ames, Ph.D., and Ramesh Tentu, M.D.*, all of Mayo Clinic. (*These authors worked on this study while at Mayo Clinic but have since left.)
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit mayoclinic.org/news.
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.
About the Center for Individualized Medicine
The Center for Individualized Medicine discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient.
Source: Newswise
Epigenetics
In the recent years 'epigenetics' represents inheritable changes in gene expression that do not include DNA alterations.
Advertisement
The study revealed genomic alterations that might be susceptible to chemotherapy in the majority of patients (72 percent). Accordingly, an implied therapeutic road map for small intestine carcinoids might feature many related, but distinct, paths defined by individualized approaches and pharmacogenomics.
Dr. Banck's team, including Mayo oncologist and senior author Andreas Beutler, M.D., sequenced the genes of small intestine neuroendocrine tumors from 48 patients, along with the normal (or germline) tissue of those same 48 patients. Comparative analysis of the 96 whole exome sequences revealed that small intestine neuroendocrine tumors carry low numbers of point mutations and characteristic recurrent patterns of gene duplications and losses.
The study was supported by grants from the Mayo Clinic Center for Individualized Medicine, Mayo Clinic, and The Richard M. Schulze Family Foundation.
Study authors also include Rahul Kanwar, Amit Kulkarni, M.B.B.S., Ganesh Boora, M.B.B.S., M.D., Franziska Metge*, Benjamin Kipp, Ph.D., Lizhi Zhang, M.D., Erik Thorland, Ph.D., Kay Minn*, Bruce Eckloff, Eric Wieben, Ph.D., Yanhong Wu, Ph.D., Julie M. Cunningham, Ph.D., David Nagorney, M.D., Judith Gilbert*, Matthew Ames, Ph.D., and Ramesh Tentu, M.D.*, all of Mayo Clinic. (*These authors worked on this study while at Mayo Clinic but have since left.)
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit mayoclinic.org/news.
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.
About the Center for Individualized Medicine
The Center for Individualized Medicine discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient.
Source: Newswise
Genetic Testing of Diseases
Genetic testing helps to confirm a genetic condition in an individual and involves q complex laboratory techniques
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Genetics & Stem Cells News
Among MS patients, the stem cells showed a neuroprotective role, guarding nerve cells from further decline.
New possibilities for research on digestive diseases have been set by complete decoding of the Y chromosome.
UK has given the green light to the world's inaugural gene therapy for sickle-cell disease and thalassemia.
1 in 25 people had a genotype linked to short lifetime, which includes BRCA2 and LDLR genes, that reduced lifespan by seven years, and six years respectively.
The study findings help redefine osteoarthritis as a reversible loss of key cartilage stem cells, not just 'wear and tear'."